.avif)
RET Mutation Test - Thyroid Medullary Cancer Biomarker
Detects inherited RET gene mutations that indicate risk for multiple endocrine neoplasia type 2 (MEN2), enabling early interventions and family testing. Identifying carriers before symptoms appear helps prevent advanced medullary thyroid carcinoma, pheochromocytoma and primary hyperparathyroidism through timely surveillance and prophylactic treatment.
RET Mutation Test - Thyroid Medullary Cancer Biomarker
Identifies inherited RET gene mutations that raise risk for medullary thyroid carcinoma and MEN2-related endocrine tumors, enabling targeted surveillance and family testing. Knowing your RET status supports timely interventions (including preventive surgery or earlier treatment) that can greatly reduce the chance of advanced thyroid cancer and related complications.
Calcitonin Test - Thyroid Medullary Cancer Biomarker
A blood calcitonin test screens for elevated calcitonin from thyroid C‑cells to detect medullary thyroid carcinoma, C‑cell hyperplasia, and to monitor for recurrence after treatment. Early detection helps identify malignant thyroid nodules sooner so treatment can begin before the cancer spreads.
CEA Test - Thyroid Medullary Cancer Biomarker
A CEA blood test measures carcinoembryonic antigen to help monitor colorectal cancer treatment and detect recurrence early; it can also assist clinicians in assessing other cancers (e.g., pancreatic, gastric, lung). By flagging rising levels sooner, it helps catch recurrence or progression early so treatment can be adjusted to reduce the risk of advanced disease and complications.
.svg)
.png)